Tuberculosis (TB) is a devastating and common infectious disease in Nepal. Seventy thousand Nepali people fall sick with TB every year and 47 people die every day.
Yet, TB is preventable and treatable- no-one should die of TB in the 21st century. Countries like Nepal struggle to provide basic health services, particularly to remote populations, and so TB continues to cause untold suffering among the poorest in our communities.
Impact TB 2, generously funded by the Nick Simons Foundation, continued our work to design and test innovations for patient centric models of TB care and cure in the Nepali context. The project implemented an intensive active case finding strategy with high GeneXpert coverage in four districts of Nepal: Chitwan, Mahottari, Pyuthan, and Bardiya and also piloted the WHO-recommended 12-dose 3HP short TB preventive therapy regimen in Chitwan and Pyuthan.
THE IMPACT of IMPACT TB: Our results
The project gathered evidence from pilot interventions to inform national TB case finding and prevention strategies through data analysis including project yield, health economic evaluations, mathematical models, and stakeholder feedback.
• We showed that social contact tracing coupled with GeneXpert testing is an appropriate and high yield strategy for increasing TB active case finding in Nepal.
• The 3HP TB preventive treatment has high uptake and completion rates in Nepali communities and should be prioritised in the national strategy.
• Our patient costing surveys highlighting the catastrophic costs faced by many people affected by TB in Nepal led to the first comprehensive national TB patient cost survey, which will be analysed and published in late 2024.
• Findings from IMPACT TB have been incorporated into national, regional and international guidelines.
PROJECT PERIOD: March 2021 to February 2023
People affected with Tuberculosis